Tag Archives: R&D

Patients are the Missing Link in R&D

Elias Zerhouni

An architect does not wait until construction begins to show clients a blueprint. Neither does a caterer prepare a banquet meal without consulting first with the host. In biopharmaceutical science, however, for too long we have developed medicines without engaging patients early on and throughout the process. If scientific innovation is to truly be innovative, we need to be more interested in the people our products will help. We need to rethink innovation. The model we’ve used in healthcare Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Auto Injectors & Pen Injectors: Differentiating Products in Asia Pacific

Steven Kaufman

Asia Pacific, with its mix of mature and emerging pharmaceutical markets and strong indigenous R&D capabilities, has no doubt already become a prominent driving force for the current and future global pharmaceutical industry with reports projecting the industry in this region to grow at a CAGR of 10 percent between 2012 and 2015. As the third largest pharmaceutical market following North America and Europe, Asia Pacific offers an immense potential for multinational pharmaceutical companies not Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Data Exclusivity Protects Innovators and Assures Investors

medical_research_thumb

Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps companies secure much-needed venture capital funding, which is the lifeblood of the industry. A failure to include substantial data exclusivity would undermine incentives to invest in biomedical innovation and thus would slow progress in the development of breakthrough therapies to improve the health and lives of patients Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Research: Working Together Toward Cures

Jim Greenwood

Modern biomedical innovation and the discovery of new cures and therapies for devastating diseases require robust collaboration and coordination among industry, research institutions and physicians. By bringing together the brightest minds in medical research, our nation’s research enterprise has successfully brought hundreds of new drugs, biologics, and vaccines to market in recent years and developed a wealth of clinical prescribing information. Ongoing research is advancing the fight against some of humanity’s worst scourges, such as Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,